Pre-made Vopratelimab benchmark antibody ( Whole mAb, anti-ICOS therapeutic antibody, Anti-AILIM/CD278/CVID1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Vopratelimab biosimilar, Whole mAb, Anti-ICOS Antibody: Anti-AILIM/CD278/CVID1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

An agonistic humanized monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential antineoplastic activity. Upon administration, vopratelimab targets and binds to ICOS expressed on certain T cells.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-629-1mg	1mg	3090
GMP-Bios-ab-629-10mg	10mg	Inquiry
GMP-Bios-ab-629-100mg	100mg	Inquiry
GMP-Bios-ab-629-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Vopratelimab biosimilar, Whole mAb, Anti-ICOS Antibody: Anti-AILIM/CD278/CVID1 therapeutic antibody
INN Name	Vopratelimab
Target	ICOS
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2017
Year Recommended	2018
Companies	Jounce Therapeutics
Conditions Approved	na
Conditions Active	Solid tumours;Urogenital cancer;Non-small cell lung cancer
Conditions Discontinued	na
Development Tech	na